There have been 56 varieties of anti-hypertension chemical drugs recorded in the Chinese National Catalog of Basic Medical Insurance (2009 version), and Calcium Channel Blocker is one major category clinically. The major varieties include totally 14 drugs such as amlodipine, nifedipine, benidipine, felodipine, levamlodipine, lacidipine, lercanidipine, nicardipine, cilnidipine, nitrendipine, Amlodipine L-Aspriticacid, nimodipine, verapamil and diltiazem.
The cardiovascular system drug market of sample hospitals of 22 key cities of China in 2013 had reached 17.214 billion yuan, with the year-on-year growth of 12.03%, according to the data of China National Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology of the P.R.C., wherein, the anti-hypertension drug market accounted for 30%, which mainly consisted of Calcium Channel Blocker, angiotensin II receptor inhibitor, angiotensin converting enzyme inhibitor, β receptor blocker, diuretics and other subclasses for anti-hypertension.
The awareness rate, treatment rate and control rate are somewhat improved under the universal education of China regarding knowledge relevant to hypertension; with the sound establishment of universal medical insurance in China, the scale of anti-hypertension drug market takes on an increasing situation and there will be particularly fierce competitions in the pharmaceutical market.
